FDA places partial hold on BioNTech-MediLink ADC after multiple deaths - Endpoints News endpts.com Submitted by endpointsnews6292 on June 18, 2024 at 6:47 PM in business No comments 12
Rare pediatric disease vouchers face uncertain future after September - Endpoints News endpts.com Submitted by endpointsnews6292 on June 16, 2024 at 9:25 AM in health No comments 32
Paxlovid did not beat placebo in Stanford-led long Covid study - Endpoints News endpts.com Submitted by endpointsnews6292 on June 12, 2024 at 2:20 AM in health No comments 41
'Invisible hand' of inherited genetics can drive cancer risk, new study suggests - Endpoints News endpts.com Submitted by endpointsnews6292 on June 2, 2024 at 12:28 AM in health No comments 25
Summit Therapeutics’ stock soars as biotech says its cancer drug beat Keytruda in Phase 3 - Endpoints News endpts.com Submitted by endpointsnews6292 on June 1, 2024 at 3:13 AM in business No comments 56
Merck returns to lucrative eye disease market in up to $3B deal for EyeBio - Endpoints News endpts.com Submitted by endpointsnews6292 on May 30, 2024 at 3:20 PM in business No comments 43
J&J makes another I&I acquisition with $1.25B deal for Numab's Yellow Jersey - Endpoints News endpts.com Submitted by endpointsnews6292 on May 29, 2024 at 6:32 PM in business No comments 16
Novo’s semaglutide hits secondary endpoints in Ph3 kidney disease trial, cutting risks of cardio events and death - Endpoints News endpts.com Submitted by endpointsnews6292 on May 25, 2024 at 5:54 PM in news No comments 2
Pfizer announces another $1.5B in cost cuts — and plans for more to come - Endpoints News endpts.com Submitted by endpointsnews6292 on May 23, 2024 at 6:30 PM in business No comments 61
AstraZeneca targets $80B revenue, 20 new drugs by 2030 - Endpoints News endpts.com Submitted by endpointsnews6292 on May 22, 2024 at 3:07 PM in business No comments 11
FDA approves Amgen's T cell engager in aggressive form of lung cancer - Endpoints News endpts.com Submitted by endpointsnews6292 on May 17, 2024 at 8:05 PM in business No comments 6
Cytokinetics lifts curtain on Phase 3 aficamten data, commercial launch prep underway - Endpoints News endpts.com Submitted by endpointsnews6292 on May 14, 2024 at 1:33 PM in business No comments 43
Takeda bets $100M upfront on AC Immune's anti-amyloid Alzheimer's vaccine - Endpoints News endpts.com Submitted by endpointsnews6292 on May 14, 2024 at 11:15 AM in business No comments 1
Flagship commits $50M to new startup that scours viral proteins for new drugs - Endpoints News endpts.com Submitted by endpointsnews6292 on May 8, 2024 at 10:00 AM in health No comments 49
Exclusive: New York biotech debuts with $16M to find new ways to make solid cancer cell therapies - Endpoints News endpts.com Submitted by endpointsnews6292 on May 7, 2024 at 11:00 AM in technology No comments 50
Pfizer hires Citi analyst Baum to oversee portfolio strategy - Endpoints News endpts.com Submitted by endpointsnews6292 on May 7, 2024 at 10:45 AM in business No comments 8
Labcorp expands Alzheimer's blood tests for doctors and drugmakers - Endpoints News endpts.com Submitted by endpointsnews6292 on March 21, 2024 at 11:00 AM in health No comments 21
Gates-backed PhIII study tuberculosis vaccine study gets underway - Endpoints News endpts.com Submitted by endpointsnews6292 on March 20, 2024 at 1:00 PM in health No comments 27
Kyverna surges after IPO, and CEO lays out plans for cell therapy in immune diseases - Endpoints News endpts.com Submitted by endpointsnews6292 on February 9, 2024 at 9:08 PM in business No comments 14
Kyverna’s $319M IPO adds to fervor for autoimmune cell therapies - Endpoints News endpts.com Submitted by endpointsnews6292 on February 9, 2024 at 9:31 AM in business No comments 36
Beam Therapeutics CEO on CRISPR’s future, sickle cell research: The Endpoints Slack interview - Endpoints News endpts.com Submitted by endpointsnews6292 on February 6, 2024 at 3:56 PM in health No comments 13
Pliant's chronic liver disease drug has consistent safety across dose ranges, PhII data show - Endpoints News endpts.com Submitted by endpointsnews6292 on February 6, 2024 at 12:23 PM in business No comments 36
Gene editing startup Metagenomi finally sets IPO range, as preclinical biotech eyes $87M - Endpoints News endpts.com Submitted by endpointsnews6292 on February 6, 2024 at 12:23 PM in business No comments 37
Due to 'overwhelming demand,' Sanofi and AstraZeneca's RSV antibody to be in limited supply - Endpoints News endpts.com Submitted by endpointsnews6292 on February 2, 2024 at 12:19 PM in health No comments 47
CMS details program to use outcomes-based agreements to pay for sickle cell gene therapies - Endpoints News endpts.com Submitted by endpointsnews6292 on February 1, 2024 at 4:17 PM in health No comments 47